Back to discover
Drug

Vestronidase alfa

Approved · EMA

Also known as Mepsevii, Recombinant human beta-glucuronidase.

RxNorm1989819UNII7XZ4062R17
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Mepsevii (EMA)

Regulatory2018-08-23EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vestronidase alfa
Aliases & brands
MepseviiRecombinant human beta-glucuronidase
RxNorm CUI
1989819
UNII
7XZ4062R17
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2018-08-23
Latest approval
2018-08-23
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2018-08-23Approval
Approval: Mepsevii (EMA)

Indication: Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.